[Research Advances of m⁶A RNA Methylation in Non-small Cell Lung Cancer].

Abstract

N6-methyladenosine is one of the most prevalent mRNA modification in eukaryotes. The regulation of this pervasive mark is a dynamic and reversible process. m⁶A RNA methylation is catalyzed by m⁶A writers, removed by m⁶A erasers and recognized by m⁶A readers, thereby regulating multiple RNA processes including alternative splicing, nuclear export, degradation and translation. Accumulated evidence suggests that m⁶A modification plays a crucial role in the pathogenic mechanism and malignant progression in non-small cell lung cancer (NSCLC), including cell survival, proliferation, migration, invasion, tumor metastasis and drug resistance. Moreover, the expression of m⁶A and its related proteins are dysregulated in clinical samples and circulating tumor cells (CTCs) of lung cancer patients, indicating that m⁶A modification may serve as a novel potential biomarker for the diagnosis and prognosis of lung cancer. In this review, by summarizing a great number of recent reports related to m⁶A's function and its modulators, we aim to provide a new insight on the early diagnosis and drug development in NSCLC therapy.
.

• Authors: Hongli Pan, Xuebing Li, Chen Chen, Yaguang Fan, Qinghua Zhou
• Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer (Zhongguo Fei Ai Za Zhi) Vol. 23 Issue 11 Pg. 961-969 (Nov 20 2020) ISSN: 1999-6187 [Electronic] China
• PMID: 33203198 (Publication Type: Journal Article, Review)

Chemical References

• RNA, Messenger
• Adenosine

Topics

• Adenosine (metabolism)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, metabolism)
• Humans
• Lung Neoplasms (drug therapy, genetics, metabolism)
• Methylation
• Molecular Targeted Therapy
• RNA, Messenger (metabolism)